ScholarLens Back to search
2017•Medycyna FaktówOpen access

Inhaled corticosteroids and long-acting β2-agonists in asthma and COPD treatment. Fluticasone propionate and salmeterol for long-term control of asthma and COPD

Andrzej Obojski

Open full text 0 citations

Abstract

Inhaled corticosteroids and long-acting β2-agonists are key therapeutic options for obstructive lung diseases management. A mechanism of action and indications for therapy and treatment recommendations for asthma and COPD are discussed.

About this research paper

What this paper is about

Inhaled corticosteroids and long-acting β2-agonists are key therapeutic options for obstructive lung diseases management. A mechanism of action and indications for therapy and treatment recommendations for asthma and COPD are discussed.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Inhaled corticosteroids and long-acting β2-agonists are key therapeutic options for obstructive lung diseases management. A mechanism of action and indications for therapy and treatment recommendations for asthma and COPD are discussed.

Key concepts: Salmeterol, Fluticasone propionate, Medicine, COPD, Asthma, Fluticasone, Inhaled corticosteroids, Formoterol

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Inhaled corticosteroids and long-acting β2-agonists in asthma and COPD treatment. Fluticasone propionate and salmeterol for long-term control of asthma and COPD — Research Paper | ScholarLens